With very close ties to Cornell on many levels, Glycobia is leveraging a proven technology platform for bottom-up assembly of diverse cancer-related glycan antigens that enables discovery of novel cancer immunotherapeutics. This technology is described as generating glycan-specific antibodies by stimulating an immune response to novel glycoconjugates comprising bioengineered human glycan structures. This breakthrough allows privileged access to therapeutically validated glycan targets that are not naturally recognized by the immune system. Using this approach, Glycobia is actively developing immunotherapies against structural signatures of cancer.
